Header Logo

Connection

C OSBORNE to Aged, 80 and over

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Aged, 80 and over.
C OSBORNE
Connection Strength
0.169
Aged, 80 and over
  1. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
    View in: PubMed
    Score: 0.024
  2. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21.
    View in: PubMed
    Score: 0.017
  3. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13.
    View in: PubMed
    Score: 0.015
  4. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
    View in: PubMed
    Score: 0.014
  5. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501.
    View in: PubMed
    Score: 0.010
  6. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85.
    View in: PubMed
    Score: 0.008
  7. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb; 10(2):304-10.
    View in: PubMed
    Score: 0.007
  8. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
    View in: PubMed
    Score: 0.006
  9. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76.
    View in: PubMed
    Score: 0.006
  10. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
    View in: PubMed
    Score: 0.006
  11. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
    View in: PubMed
    Score: 0.006
  12. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
    View in: PubMed
    Score: 0.006
  13. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
    View in: PubMed
    Score: 0.006
  14. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer. Invest New Drugs. 1989 Jul; 7(2-3):243-5.
    View in: PubMed
    Score: 0.005
  15. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol. 2006 Feb; 20(2):311-20.
    View in: PubMed
    Score: 0.004
  16. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
    View in: PubMed
    Score: 0.004
  17. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
    View in: PubMed
    Score: 0.004
  18. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
    View in: PubMed
    Score: 0.004
  19. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
    View in: PubMed
    Score: 0.004
  20. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May; 79(2):207-11.
    View in: PubMed
    Score: 0.004
  21. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
    View in: PubMed
    Score: 0.004
  22. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
    View in: PubMed
    Score: 0.003
  23. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.003
  24. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.